These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 12443714

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
    Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M, Ghossein RA.
    Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
    [Abstract] [Full Text] [Related]

  • 3. Heparanase-1 and Cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas.
    Zhu Y, He HC, Yuan F, Zhang J, Rui WB, Zhao JP, Shen ZJ, Ning G.
    Endocrine; 2010 Aug; 38(1):93-9. PubMed ID: 20960108
    [Abstract] [Full Text] [Related]

  • 4. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.
    Salmenkivi K, Haglund C, Ristimäki A, Arola J, Heikkilä P.
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5615-9. PubMed ID: 11701743
    [Abstract] [Full Text] [Related]

  • 5. [Pheochromocytomas in adrenal medulla or extra-adrenal and multiple endocrine neoplasms:a clinicopathologic analysis of 181 cases].
    Jiang CX, Zeng Z, Wang T, Liu X, Liu R, Li Y.
    Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):762-6. PubMed ID: 22336161
    [Abstract] [Full Text] [Related]

  • 6. Survivin: a novel neuroendocrine marker for pheochromocytoma.
    Koch CA, Vortmeyer AO, Diallo R, Poremba C, Giordano TJ, Sanders D, Bornstein SR, Chrousos GP, Pacak K.
    Eur J Endocrinol; 2002 Mar; 146(3):381-8. PubMed ID: 11888845
    [Abstract] [Full Text] [Related]

  • 7. Pheochromocytomas: can malignant potential be predicted?
    John H, Ziegler WH, Hauri D, Jaeger P.
    Urology; 1999 Apr; 53(4):679-83. PubMed ID: 10197840
    [Abstract] [Full Text] [Related]

  • 8. Remarkably suppressed manganese superoxide dismutase activity in malignant pheochromocytoma.
    Nakada T, Kubota Y, Sasagawa I, Yagisawa T, Watanabe M, Ishigooka M.
    J Urol; 1995 Jun; 153(6):1787-90. PubMed ID: 7752317
    [Abstract] [Full Text] [Related]

  • 9. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
    Feng C, Li HZ, Yan WG, Gao JG, Xu WF, Luo YF, Cao JL.
    Zhonghua Wai Ke Za Zhi; 2007 Dec 15; 45(24):1697-700. PubMed ID: 18476530
    [Abstract] [Full Text] [Related]

  • 10. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
    Elder EE, Xu D, Höög A, Enberg U, Hou M, Pisa P, Gruber A, Larsson C, Bäckdahl M.
    Mod Pathol; 2003 Mar 15; 16(3):246-55. PubMed ID: 12640105
    [Abstract] [Full Text] [Related]

  • 11. Clinical experience over 48 years with pheochromocytoma.
    Goldstein RE, O'Neill JA, Holcomb GW, Morgan WM, Neblett WW, Oates JA, Brown N, Nadeau J, Smith B, Page DL, Abumrad NN, Scott HW.
    Ann Surg; 1999 Jun 15; 229(6):755-64; discussion 764-6. PubMed ID: 10363888
    [Abstract] [Full Text] [Related]

  • 12. Heparanase expression correlates with malignant potential in human colon cancer.
    Nobuhisa T, Naomoto Y, Ohkawa T, Takaoka M, Ono R, Murata T, Gunduz M, Shirakawa Y, Yamatsuji T, Haisa M, Matsuoka J, Tsujigiwa H, Nagatsuka H, Nakajima M, Tanaka N.
    J Cancer Res Clin Oncol; 2005 Apr 15; 131(4):229-37. PubMed ID: 15625607
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic role of inhibin α-subunit and inhibin/activin β-subunit in adrenal cortical and medullary tumors in Egyptian patients.
    Elmoneim HM, Samaka RM, Ali H.
    Appl Immunohistochem Mol Morphol; 2012 Oct 15; 20(5):462-9. PubMed ID: 22417854
    [Abstract] [Full Text] [Related]

  • 14. Elevated levels of telomerase activity in malignant pheochromocytoma.
    Kubota Y, Nakada T, Sasagawa I, Yanai H, Itoh K.
    Cancer; 1998 Jan 01; 82(1):176-9. PubMed ID: 9428495
    [Abstract] [Full Text] [Related]

  • 15. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis.
    Xu X, Quiros RM, Maxhimer JB, Jiang P, Marcinek R, Ain KB, Platt JL, Shen J, Gattuso P, Prinz RA.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5968-79. PubMed ID: 14676122
    [Abstract] [Full Text] [Related]

  • 16. Stathmin as a marker for malignancy in pheochromocytomas.
    Björklund P, Cupisti K, Fryknäs M, Isaksson A, Willenberg HS, Akerström G, Hellman P, Westin G.
    Exp Clin Endocrinol Diabetes; 2010 Jan 01; 118(1):27-30. PubMed ID: 19449284
    [Abstract] [Full Text] [Related]

  • 17. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma.
    Patterson E, Webb R, Weisbrod A, Bian B, He M, Zhang L, Holloway AK, Krishna R, Nilubol N, Pacak K, Kebebew E.
    Endocr Relat Cancer; 2012 Apr 01; 19(2):157-66. PubMed ID: 22241719
    [Abstract] [Full Text] [Related]

  • 18. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.
    Suh I, Shibru D, Eisenhofer G, Pacak K, Duh QY, Clark OH, Kebebew E.
    Ann Surg; 2009 Dec 01; 250(6):983-90. PubMed ID: 19661783
    [Abstract] [Full Text] [Related]

  • 19. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma.
    Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, Israel MA.
    J Clin Oncol; 1989 Nov 01; 7(11):1720-5. PubMed ID: 2809684
    [Abstract] [Full Text] [Related]

  • 20. Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas.
    Luo Z, Li J, Qin Y, Ma Y, Liang X, Xian J, Lu D, Wei M, Yang JY, Yang MQ, He Z.
    Endocr Pathol; 2006 Nov 01; 17(4):387-98. PubMed ID: 17525487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.